Respiratorius AB (XSAT:RESP) Ending Cash Position: kr4.66 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:RESP Respiratorius AB XSAT:RESP
34 GF Score
Price kr2.32
View Full Analysis

What is Respiratorius AB Ending Cash Position?

Respiratorius AB XSAT:RESP -4.53% 34 Ending Cash Position is kr4.66 Mil as of Mar. 2026. GuruFocus rates XSAT:RESP with a GF Score™ of 34/100.

Respiratorius AB's Ending Cash Position for the quarter that ended in Mar. 2026 was kr4.66 Mil.

Respiratorius AB's quarterly Ending Cash Position declined from Sep. 2025 (kr8.22 Mil) to Dec. 2025 (kr7.36 Mil) and declined from Dec. 2025 (kr7.36 Mil) to Mar. 2026 (kr4.66 Mil).

Respiratorius AB's annual Ending Cash Position increased from Dec. 2023 (kr1.95 Mil) to Dec. 2024 (kr7.65 Mil) but then declined from Dec. 2024 (kr7.65 Mil) to Dec. 2025 (kr7.36 Mil).

Respiratorius AB Ending Cash Position Related Terms

Respiratorius AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Respiratorius AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Respiratorius AB Ending Cash Position Chart

Respiratorius AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.69 0.00 1.95 7.65 7.36

Respiratorius AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Apr22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.15 3.13 8.22 7.36 4.66
XSAT:RESP
34GF Score
Respiratorius AB XSAT:RESP
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Respiratorius AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Respiratorius AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7.646+-0.288
=7.36

Respiratorius AB's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=7.358+-2.702
=4.66

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr4.66 Mil mean?
Respiratorius AB (XSAT:RESP) has a Ending Cash Position of kr4.66 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Respiratorius AB and its competitors.
Is Respiratorius AB's Ending Cash Position too high?
Respiratorius AB's current Ending Cash Position is kr4.66 Mil. Overall, Respiratorius AB has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Respiratorius AB's Ending Cash Position compare to VRTX and REGN?
Respiratorius AB's Ending Cash Position of kr4.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Respiratorius AB and its competitors. Respiratorius AB's current Ending Cash Position is kr4.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Respiratorius AB stock overvalued right now?
Respiratorius AB (XSAT:RESP) has a current Ending Cash Position of kr4.66 Mil. The current Ending Cash Position is kr4.66 Mil. Respiratorius AB's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Respiratorius AB (XSAT:RESP), the current Ending Cash Position is kr4.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Respiratorius AB Business Description

Address Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
34GF Score

Get the complete analysis for XSAT:RESP

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.32
Price